Semaglutide-induced Wernicke encephalopathy: a comprehensive analysis.

IF 3.3 3区医学 Q2 NUTRITION & DIETETICS

European Journal of Clinical Nutrition Pub Date : 2025-09-04 DOI:10.1038/s41430-025-01653-7

Cécile Gras, Victoria De Wit, Nacima Oussedik, Sylvie Daclin, Venceslas Bourdin, Delphine Callot, Ghiles Chegrani, Claire Rives-Lange, Laurent Chouchana

{"title":"Semaglutide-induced Wernicke encephalopathy: a comprehensive analysis.","authors":"Cécile Gras, Victoria De Wit, Nacima Oussedik, Sylvie Daclin, Venceslas Bourdin, Delphine Callot, Ghiles Chegrani, Claire Rives-Lange, Laurent Chouchana","doi":"10.1038/s41430-025-01653-7","DOIUrl":null,"url":null,"abstract":"<p><p>Although GLP-1 receptors analogues (RAs) benefits-risks profile has been largely documented in diabetes, higher dosages recently approved in obesity still require further assessment. We describe here the case of a 49-year-old female patient treated with semaglutide for obesity, who presented with Wernicke encephalopathy in a context of iterative vomiting and reduced food intake. Eighteen other cases of Wernicke encephalopathy were reported in literature and in the WHO global safety database (VigiBase). A context of nausea/vomiting or reduced food intake is described in 68% of cases, with weight loss ranging from -3.5 to -13.3 kg/month over 3 to 6 months. Disproportionality analysis in VigiBase showed that Wernicke encephalopathy was disproportionately reported with semaglutide, tirzepatide and the whole GLP-1RAs group. Altogether, this comprehensive analysis supports a safety signal regarding the risk of Wernicke encephalopathy with GLP-1RAs, which requires a prompt assessment, accounting for the growing use of these drugs.</p>","PeriodicalId":11927,"journal":{"name":"European Journal of Clinical Nutrition","volume":" ","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Clinical Nutrition","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41430-025-01653-7","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}

引用次数: 0

Abstract

Although GLP-1 receptors analogues (RAs) benefits-risks profile has been largely documented in diabetes, higher dosages recently approved in obesity still require further assessment. We describe here the case of a 49-year-old female patient treated with semaglutide for obesity, who presented with Wernicke encephalopathy in a context of iterative vomiting and reduced food intake. Eighteen other cases of Wernicke encephalopathy were reported in literature and in the WHO global safety database (VigiBase). A context of nausea/vomiting or reduced food intake is described in 68% of cases, with weight loss ranging from -3.5 to -13.3 kg/month over 3 to 6 months. Disproportionality analysis in VigiBase showed that Wernicke encephalopathy was disproportionately reported with semaglutide, tirzepatide and the whole GLP-1RAs group. Altogether, this comprehensive analysis supports a safety signal regarding the risk of Wernicke encephalopathy with GLP-1RAs, which requires a prompt assessment, accounting for the growing use of these drugs.

查看原文本刊更多论文

semaglutide诱导的韦尼克脑病：一项综合分析。

尽管GLP-1受体类似物（RAs）在糖尿病中的获益-风险分析已被大量记录，但最近被批准用于肥胖的更高剂量仍需要进一步评估。我们在这里描述了一个49岁的女性患者接受西马鲁肽治疗肥胖的病例，她在反复呕吐和食物摄入减少的情况下表现为韦尼克脑病。文献和世卫组织全球安全数据库（VigiBase）中报告了另外18例韦尼克脑病。68%的病例出现恶心/呕吐或食物摄入减少，3至6个月内体重减轻-3.5至-13.3 kg/月。VigiBase的歧化分析显示，在西马鲁肽、替西帕肽和整个GLP-1RAs组中，韦尼克脑病的报告不成比例。总之，这一综合分析支持GLP-1RAs与韦尼克脑病风险有关的安全信号，这需要及时评估，考虑到这些药物的使用日益增加。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Clinical Nutrition 医学-营养学

CiteScore

10.60

自引率

2.10%

发文量

189

审稿时长

3-6 weeks

期刊介绍： The European Journal of Clinical Nutrition (EJCN) is an international, peer-reviewed journal covering all aspects of human and clinical nutrition. The journal welcomes original research, reviews, case reports and brief communications based on clinical, metabolic and epidemiological studies that describe methodologies, mechanisms, associations and benefits of nutritional interventions for clinical disease and health promotion. Topics of interest include but are not limited to: Nutrition and Health (including climate and ecological aspects) Metabolism & Metabolomics Genomics and personalized strategies in nutrition Nutrition during the early life cycle Health issues and nutrition in the elderly Phenotyping in clinical nutrition Nutrition in acute and chronic diseases The double burden of ''malnutrition'': Under-nutrition and Obesity Prevention of Non Communicable Diseases (NCD)